Michael Davidson
Chief Executive Officer bij FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Vermogen: 13 045 $ op 31-03-2024
Profiel
Michael H.
Davidson was the founder of Omthera Pharmaceuticals, Inc. (founded in 2008) where he served as the Chief Medical Officer from 2008 to 2013.
He was also the founder of Chicago Center for Clinical Research (founded in 1987) where he held the position of President & Chief Executive Officer from 1987 to 2008.
Additionally, he co-founded Corvidia Therapeutics, Inc. (founded in 2016) and served as the Co-Chief Scientific & Medical Officer from 2018 to 2020.
Furthermore, he founded Trofi Nutritionals, Inc. in 2021 and currently holds the position of Director & Chief Scientific Officer.
Dr. Davidson is also the founder of SonoThera, Inc...His current job positions include Chief Executive Officer & Executive Director at NewAmsterdam Pharma BV and NewAmsterdam Pharma Holding BV since 2020, President, Chief Executive Officer & Director at NewAmsterdam Pharma Co. NV since 2022, Independent Director at Tenax Therapeutics, Inc. since 2021, Director at Sonogene LLC, Non-Executive Director at Silence Therapeutics Plc since 2021, Director-Lipid Clinic & Professor at The University of Chicago, Director at Preventive Cardiology Institute, Inc., Director at Abcentra, Inc. since 2021, Director at Midwest Lipid Association, Director at Inositec AG since 2020, Director at Jocasta Neuroscience, Inc., Director at NanoPhoria Srl, Member of American College of Chest Physicians, Member of American College of Cardiology Foundation, and Professor at The University of Chicago Department of Medicine since 2007.
His former job positions include Independent Director at ABIONYX Pharma SA from 2015 to 2019, Independent Director at Caladrius Biosciences, Inc., Director at Cerenis Therapeutics, Inc. from 2015 to 2019, and President of National Lipid Association from 2010 to 2011.
In terms of education, Dr. Davidson completed his undergraduate studies at Northwestern University and obtained a doctorate degree from The Ohio State University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SILENCE THERAPEUTICS PLC
0.01% | 01-03-2024 | 12 993 ( 0.01% ) | 11 434 $ | 31-07-2023 |
TENAX THERAPEUTICS, INC.
0.02% | 20-03-2024 | 380 ( 0.02% ) | 1 611 $ | 31-03-2024 |
01-01-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Michael Davidson
Bedrijven | Functie | Begin |
---|---|---|
SILENCE THERAPEUTICS PLC | Director/Board Member | 06-01-2021 |
TENAX THERAPEUTICS, INC. | Director/Board Member | 25-02-2021 |
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Chief Executive Officer | 01-11-2022 |
Sonogene LLC | Director/Board Member | - |
NanoPhoria Srl
NanoPhoria Srl Drugstore ChainsRetail Trade NanoPhoria Srl is an Italian company that operates as a non-viral drug delivery platform. The company is based in Milan, Italy. The company was founded by Daniele Catalucci, Michele Iafisco, Alessio Alogna, Claudio de Luca. Claudio de Luca has been the CEO since incorporation. | Director/Board Member | - |
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Founder | - |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Chief Executive Officer | 01-08-2020 |
Jocasta Neuroscience, Inc.
Jocasta Neuroscience, Inc. BiotechnologyHealth Technology Jocasta Neuroscience, Inc. provides biological products development services. The company is based in New Castle, DE. | Director/Board Member | - |
The University of Chicago | Corporate Officer/Principal | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Eerdere bekende functies van Michael Davidson
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░ ░░░░░░░░ ░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Michael Davidson
Northwestern University | Undergraduate Degree |
The Ohio State University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
TENAX THERAPEUTICS, INC. | Health Technology |
SILENCE THERAPEUTICS PLC | Commercial Services |
ABIONYX PHARMA | Health Technology |
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
Bedrijven in privébezit | 19 |
---|---|
Sonogene LLC | |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
Chicago Center for Clinical Research
Chicago Center for Clinical Research Miscellaneous Commercial ServicesCommercial Services Part of CRA Holdings LLC, Chicago Center for Clinical Research is an American company that provides clinical research services. The private company was founded by Michael H. Davidson. | Commercial Services |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
American College of Chest Physicians
American College of Chest Physicians Miscellaneous Commercial ServicesCommercial Services The American College of Chest Physicians is a leading organization in clinical chest medicine, with over 19,000 members providing patient care in pulmonary, critical care, and sleep medicine in more than 100 countries worldwide. The non-profit company is based in Northbrook, IL. The organization offers access to clinical guidelines, new research, and clinical topic collections through their website, as well as opportunities for members to become more involved in the chest medicine community. The organization's mission is to promote the prevention, diagnosis, and treatment of chest diseases through education, communication, and research. Robert A. Musacchio has been the CEO of the company since 2015. | Commercial Services |
American College of Cardiology Foundation
American College of Cardiology Foundation Medical/Nursing ServicesHealth Services American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC. | Health Services |
Preventive Cardiology Institute, Inc. | |
Cerenis Therapeutics, Inc.
Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI. | Health Technology |
Abcentra, Inc.
Abcentra, Inc. Miscellaneous Commercial ServicesCommercial Services Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020. | Commercial Services |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Inositec AG
Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Health Technology |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The private company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
Jocasta Neuroscience, Inc.
Jocasta Neuroscience, Inc. BiotechnologyHealth Technology Jocasta Neuroscience, Inc. provides biological products development services. The company is based in New Castle, DE. | Health Technology |
NanoPhoria Srl
NanoPhoria Srl Drugstore ChainsRetail Trade NanoPhoria Srl is an Italian company that operates as a non-viral drug delivery platform. The company is based in Milan, Italy. The company was founded by Daniele Catalucci, Michele Iafisco, Alessio Alogna, Claudio de Luca. Claudio de Luca has been the CEO since incorporation. | Retail Trade |
Trofi Nutritionals, Inc.
Trofi Nutritionals, Inc. Specialty StoresRetail Trade Trofi Nutritionals, Inc. is a private company located in the US that is focused on advancing personal health management through next-generation nutritional wellness solutions. The American company works with partners to translate functional compound discoveries into nutritional solutions. | Retail Trade |
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Health Technology |
National Lipid Association
National Lipid Association Miscellaneous Commercial ServicesCommercial Services The National Lipid Association aims to improve the practice of lipid management in clinical medicine. The non-profit company is based in Jacksonville, FL and has subsidiaries in the United States. The organization's mission is to enhance lipid management in clinical medicine, and its goals are consistent with this mission statement. | Commercial Services |
Midwest Lipid Association | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |